Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)

Overview

Journal Infect Dis Rep

Publisher MDPI

Specialty Infectious Diseases

Date 2023 Dec 22

PMID 38131882

Authors

Anna Gidari

Sara Benedetti

Sara Tordi

Anastasia Zoffoli

Debora Altobelli

Elisabetta Schiaroli

Giuseppe Vittorio De Socio

Daniela Francisci

Affiliations

Soon will be listed here.

Abstract

Background: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR). This study aimed to describe a real-life experience with BIC-STR.

Methods: We retrospectively analyzed the data of people living with HIV (PLWH) on antiretroviral therapy (ART) with BIC-STR followed by the Clinic of Infectious Diseases of Perugia (Perugia, Italy) from September 2019 to February 2023.

Results: 270 PLWH were enrolled with a median follow-up time on BIC-STR of 2.2 years (IQR 1.2-2.7). In the overall population, in treatment-experienced (N = 242), in treatment-naïve (N = 28), and in population with age > 60 years old (N = 86), we observed that CD4 cell count improved in absolute number, percentage and CD4/CD8 ratio, under BIC-STR. Patients with viremia < 50 cp/mL increased in all groups. In the overall population, previous ART with TAF and nadir CD4 cell count favored immunological recovery. In the ART-experienced group, time in therapy with BIC-STR was associated with HIV-RNA undetectability. In the older group, previous opportunistic infection and advanced age were associated with lower CD4 count.

Conclusions: BIC-STR was demonstrated, in real-life, to be a valid option for a switch, such as initial ART.

Citing Articles

Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort.

Cecchini D, Brizuela M, Seleme M, Mingrone M, Copertari G, Bacelar B Rev Esp Quimioter. 2024; 38(1):40-47.

PMID: 39564653 PMC: 11758870. DOI: 10.37201/req/080.2024.

References

Chen L, Sun H, Chuang Y, Huang Y, Liu W, Lin K . Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023; 56(3):575-585. DOI: 10.1016/j.jmii.2023.01.015. View

Senneker T, Tseng A . An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors. Curr Opin HIV AIDS. 2021; 16(6):309-320. DOI: 10.1097/COH.0000000000000705. View

Rolle C, Nguyen V, Patel K, Cruz D, DeJesus E, Hinestrosa F . Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Medicine (Baltimore). 2021; 100(38):e27330. PMC: 8462546. DOI: 10.1097/MD.0000000000027330. View

Heseltine T, Hughes E, Mathew J, Murray S, Khoo S . The effect of changing to Bictegravir on lipids using real world data: A brief report. J Clin Pharm Ther. 2022; 47(12):2182-2187. DOI: 10.1111/jcpt.13789. View

Martini S, Maggi P, Gervasoni C, Onorato L, Ferrara S, Alessio L . Dynamics of Lipid Profile in Antiretroviral-Naïve HIV-Infected Patients, Treated with TAF-Based Regimens: A Multicenter Observational Study. Biomedicines. 2022; 10(12). PMC: 9775227. DOI: 10.3390/biomedicines10123164. View

Lacey A, Savinelli S, Barco E, Macken A, Cotter A, Sheehan G . Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020; 34(8):1161-1170. DOI: 10.1097/QAD.0000000000002541. View

Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R . Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. J Glob Antimicrob Resist. 2022; 30:326-334. DOI: 10.1016/j.jgar.2022.06.027. View

Chen G, Sun H, Chen L, Hsieh S, Sheng W, Liu W . Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. Int J Antimicrob Agents. 2022; 60(3):106631. DOI: 10.1016/j.ijantimicag.2022.106631. View

Calmy A, Ford N, Hirschel B, Reynolds S, Lynen L, Goemaere E . HIV viral load monitoring in resource-limited regions: optional or necessary?. Clin Infect Dis. 2006; 44(1):128-34. DOI: 10.1086/510073. View

10.

Ambrosioni J, Rojas Lievano J, Berrocal L, Inciarte A, de la Mora L, Gonzalez-Cordon A . Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022; 77(4):1133-1139. DOI: 10.1093/jac/dkab481. View

11.

Mazzitelli M, Trunfio M, Putaggio C, Sasset L, Leoni D, Menzo S . Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis. Biomedicines. 2022; 10(8). PMC: 9405513. DOI: 10.3390/biomedicines10081823. View

12.

Ryom L, de Miguel R, Cotter A, Podlekareva D, Beguelin C, Waalewijn H . Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Med. 2022; 23(8):849-858. PMC: 9545286. DOI: 10.1111/hiv.13268. View

13.

Tsai M, Sun H, Chen C, Lee C, Lee C, Liu C . Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. Int J Infect Dis. 2022; 126:39-47. DOI: 10.1016/j.ijid.2022.11.012. View

14.

Mallon P, Brunet L, Fusco J, Prajapati G, Beyer A, Fusco G . Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infect Dis. 2022; 9(1):ofab621. PMC: 8753026. DOI: 10.1093/ofid/ofab621. View

15.

Orkin C, DeJesus E, Sax P, Arribas J, Gupta S, Martorell C . Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority.... Lancet HIV. 2020; 7(6):e389-e400. DOI: 10.1016/S2352-3018(20)30099-0. View

16.

Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E . CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015; 2(3):e98-106. DOI: 10.1016/S2352-3018(15)00006-5. View

17.

Gutierrez-Lorenzo M, Rubio-Calvo D, Urda-Romacho J . [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients]. Rev Esp Quimioter. 2021; 34(4):315-319. PMC: 8329567. DOI: 10.37201/req/148.2020. View

18.

Hagins D, Kumar P, Saag M, Wurapa A, Brar I, Berger D . Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. J Acquir Immune Defic Syndr. 2021; 88(1):86-95. PMC: 8357046. DOI: 10.1097/QAI.0000000000002731. View

19.

Lazzaro A, Gentilini Cacciola E, Borrazzo C, Innocenti G, Cavallari E, Mezzaroma I . Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics (Basel). 2022; 12(1). PMC: 8774414. DOI: 10.3390/diagnostics12010076. View

20.

Gazzola L, Tagliaferri G, De Bona A, Mondatore D, Borsino C, Bini T . Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?. HIV Med. 2020; 22(2):140-145. DOI: 10.1111/hiv.12984. View